|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
|
US6077851A
(en)
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
PL199781B1
(pl)
|
1999-10-25 |
2008-10-31 |
Active Biotech Ab |
Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
|
|
EP1365794A2
(en)
|
2000-07-21 |
2003-12-03 |
Lue, Tom |
Prevention and treatment of sexual arousal disorders
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
ATE356808T1
(de)
|
2002-06-25 |
2007-04-15 |
Merck Frosst Canada Ltd |
8-(biaryl)chinolin-pde4-inhibitoren
|
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US7605166B2
(en)
|
2003-06-25 |
2009-10-20 |
Elan Pharmaceuticals Inc. |
Methods and compositions for treating rheumatoid arthritis
|
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
WO2005097162A2
(en)
|
2004-04-01 |
2005-10-20 |
Elan Pharmaceuticals, Inc. |
Steroid sparing agents and their use
|
|
EP1796710A4
(en)
|
2004-09-02 |
2010-05-26 |
Teva Pharma |
THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
EP1850840A2
(en)
|
2005-01-13 |
2007-11-07 |
Sirtris Pharmaceuticals, Inc. |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
|
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
NZ567088A
(en)
|
2005-10-19 |
2012-06-29 |
Teva Pharma |
Crystals of laquinimod sodium, and process for the manufacture thereof
|
|
WO2007048788A1
(en)
|
2005-10-26 |
2007-05-03 |
Laboratoires Serono S.A. |
Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
|
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
|
US8410115B2
(en)
|
2006-02-28 |
2013-04-02 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
US20070207141A1
(en)
|
2006-02-28 |
2007-09-06 |
Ivan Lieberburg |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
MX2008011176A
(es)
|
2006-03-03 |
2008-09-10 |
Elan Pharm Inc |
Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab.
|
|
CA2645322A1
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using cd4 antibodies
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
KR20150065951A
(ko)
|
2006-06-12 |
2015-06-15 |
테바 파마슈티컬 인더스트리즈 리미티드 |
안정한 라퀴니모드 제제
|
|
AU2007276405A1
(en)
|
2006-07-17 |
2008-01-24 |
Novartis Ag |
Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
|
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
|
EP2056818B1
(en)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
|
HRP20121034T1
(hr)
|
2006-08-17 |
2013-01-31 |
University Of Chicago |
Lijeäśenje upalnih bolesti
|
|
WO2008085484A2
(en)
|
2006-12-28 |
2008-07-17 |
Jacobus Pharmaceutical Company, Inc. |
Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
|
|
US8138201B2
(en)
|
2007-07-11 |
2012-03-20 |
Medicinova, Inc. |
Treatment of progressive neurodegenerative disease with ibudilast
|
|
EP2214657A1
(en)
|
2007-10-23 |
2010-08-11 |
UCB Pharma GmbH |
Compounds for treating demyelination conditions
|
|
EP2234485B1
(en)
|
2007-12-20 |
2013-11-13 |
Teva Pharmaceutical Industries, Ltd. |
Stable laquinimod preparations
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
KR20110048571A
(ko)
|
2008-09-03 |
2011-05-11 |
테바 파마슈티컬 인더스트리즈 리미티드 |
면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
JP2012530701A
(ja)
|
2009-06-19 |
2012-12-06 |
テバ ファーマシューティカル インダストリーズ リミティド |
多発性硬化症のラキニモドでの治療
|
|
PL2458992T3
(pl)
|
2009-07-30 |
2016-07-29 |
Teva Pharma |
Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
|
|
WO2011019375A1
(en)
|
2009-08-10 |
2011-02-17 |
Teva Pharmaceutical Industries Ltd. |
Treatment of bdnf-related disorders using laquinimod
|
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
|
CA2791711A1
(en)
|
2010-03-03 |
2011-09-09 |
Teva Pharmaceutical Industries Ltd. |
Treatment of lupus arthritis using laquinimod
|
|
DK2542079T3
(da)
|
2010-03-03 |
2014-08-25 |
Teva Pharma |
Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
|
|
SG183512A1
(en)
|
2010-03-03 |
2012-09-27 |
Teva Pharma |
Treatment of lupus nephritis using laquinimod
|
|
WO2012006538A1
(en)
*
|
2010-07-09 |
2012-01-12 |
Teva Pharmaceutical Industries Ltd. |
Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
|
|
EP2590653A4
(en)
|
2010-07-09 |
2014-01-01 |
Teva Pharma |
5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
|
|
AU2011338647A1
(en)
|
2010-12-07 |
2013-07-04 |
Teva Pharmaceutical Industries Ltd. |
Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
|
|
CA2830027C
(en)
|
2011-03-31 |
2016-04-26 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
|
IN2014MN00333A
(https=)
|
2011-07-28 |
2015-09-25 |
Teva Pharma |
|
|
AU2012286701A1
(en)
|
2011-07-28 |
2014-03-06 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
|
|
CA2851525A1
(en)
|
2011-10-12 |
2013-04-18 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
|
|
JP6215238B2
(ja)
|
2012-02-16 |
2017-10-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
AR090885A1
(es)
|
2012-05-02 |
2014-12-10 |
Teva Pharma |
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
|
US20130345257A1
(en)
|
2012-06-26 |
2013-12-26 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
BR112015007782A2
(pt)
|
2012-10-12 |
2017-07-04 |
Teva Pharma |
laquinimod para reduzir danos talâmicos na esclerose múltipla
|
|
EP2916915A4
(en)
|
2012-11-07 |
2016-06-22 |
Teva Pharma |
LAQUINIMOD AMINE SALTS
|
|
BR112015019564A2
(pt)
|
2013-02-15 |
2017-07-18 |
Teva Pharma |
tratamento de esclerose múltipla com laquinimod
|
|
US20160038435A1
(en)
|
2013-03-14 |
2016-02-11 |
Teva Pharmaceutical Industries Ltd. |
Transdermal formulations of laquinimod
|
|
US20160046582A1
(en)
|
2013-03-14 |
2016-02-18 |
Teva Pharmaceutical Industries Ltd. |
Crystals of laquinimod sodium and improved process for the manufacture thereof
|
|
HK1225969A1
(zh)
*
|
2014-01-17 |
2017-09-22 |
Teva Pharmaceutical Industries Ltd |
利用低剂量的拉喹莫德治疗克隆氏病
|